BHST

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.The expanded collaboration

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of AprilTwo-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company

Business development appointment is aligned with securing long-term customers for development and manufacturing partnershipsVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and m

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals- In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development agreement, successfully establi

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its first quarter 2026 financial results before the market opening on Thursday, May 14, 2026. The Company will also host a conference call and webcast at 8:00 a.m. U.S. Eastern Time to discuss the results and provide an update on business operations.First Quarter 2026 Earnings Call InformationDate: Thursday, May 14, 2026Time: 8:00 a.m. Eastern TimeWebcast: https://events.q4inc.com/attendee/387184352The earnings call webcast

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Ilan Sobel joins Board of Directors with focused mandate on D2C growth.Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and Operations under the CDMO.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 29, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology, today announced a strategic leadership transition designed to sharpen execution of its "two-lens strategy" across its direct-to-consumer ("D2C") business and its Contract Development and Manufacturing Organization ("CDMO") business.Dr. Zaki Rakib, the Company's

40-F - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

VINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technologyVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving blood flow and enab

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chair

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event. 38th Annual Roth Conference for Growth CompaniesDate: March 22-24, 2026Location: The Ritz-Carlton Laguna Niguel- Dana Point, CAFormat: 1x1 MeetingsSobel said: "I am pleased to announce our invitation to the 38th Annual Ro